---
figid: PMC5820294__fonc-08-00038-g001
figtitle: Signaling pathways involved in the progression of extramammary Paget’s disease
organisms:
- Homo sapiens
pmcid: PMC5820294
filename: fonc-08-00038-g001.jpg
figlink: /pmc/articles/PMC5820294/figure/F1/
number: F1
caption: Signaling pathways involved in the progression of extramammary Paget’s disease.
  (A) The aberrant activation of HER2, molecules involved in the RAS–RAF–MEK–ERK signaling
  or PI3K–AKT–mTOR signaling promote the proliferation and survival of Paget cells.
  Likewise, the androgen–androgen receptor (AR) signaling can induce the proliferation
  and survival of Paget cells. Red, Food and Drug Administration-approved drugs for
  other cancers that target aspects of this pathway. (B) The interaction of Paget
  cells with lymphatic endothelial cells (LECs) through the CXCR4–stromal cell-derived
  factor-1 (SDF-1) signaling or with CD163+Arg1+ M2 macrophages through the receptor
  activator of nuclear factor kappa-B ligand (RANKL)–RANK signaling facilitates metastasis
  of Paget cells.
papertitle: 'Metastatic Extramammary Paget’s Disease: Pathogenesis and Novel Therapeutic
  Approach.'
reftext: Keitaro Fukuda, et al. Front Oncol. 2018;8:38.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9311439
figid_alias: PMC5820294__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC5820294__F1
ndex: d0df352f-df09-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5820294__fonc-08-00038-g001.html
  '@type': Dataset
  description: Signaling pathways involved in the progression of extramammary Paget’s
    disease. (A) The aberrant activation of HER2, molecules involved in the RAS–RAF–MEK–ERK
    signaling or PI3K–AKT–mTOR signaling promote the proliferation and survival of
    Paget cells. Likewise, the androgen–androgen receptor (AR) signaling can induce
    the proliferation and survival of Paget cells. Red, Food and Drug Administration-approved
    drugs for other cancers that target aspects of this pathway. (B) The interaction
    of Paget cells with lymphatic endothelial cells (LECs) through the CXCR4–stromal
    cell-derived factor-1 (SDF-1) signaling or with CD163+Arg1+ M2 macrophages through
    the receptor activator of nuclear factor kappa-B ligand (RANKL)–RANK signaling
    facilitates metastasis of Paget cells.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ERBB2
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - AR
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MTOR
  - EPHB2
  - MAPK1
  - MAPK3
  - EIF2AK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - CCND1
  - CCND2
  - CCND3
  - CDK6
  - CDK4
  - CCR4
  - CNOT6
  - TNFRSF11A
  - CXCR4
  - CCL17
  - CDH2
  - CXCL12
  - CD8A
  - CD8B
  - Testosterone
  - Vemurafenib
  - Dabrafenib
  - androgen
  - Trametinib
  - Cobimetinib
  - Everolimus
  - Temsirolimus
  - O
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
